[HTML][HTML] A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …
EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
[HTML][HTML] From the monovalent to the nine-valent HPV vaccine
S Pils, EA Joura - Clinical Microbiology and Infection, 2015 - Elsevier
An investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine
SM Garland, M Steben, HL Sings… - The Journal of …, 2009 - academic.oup.com
Background The placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
N Muñoz, SK Kjaer, K Sigurdsson… - Journal of the …, 2010 - academic.oup.com
Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …
[HTML][HTML] Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review …
…, G Heinze, M Gaerner, C Grimm, E Joura… - Scientific reports, 2018 - nature.com
Aim of this study was to investigate the histologic outcome of cervical intraepithelial
neoplasia (CIN) during observational management. Consecutive women with histologically …
neoplasia (CIN) during observational management. Consecutive women with histologically …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen… - The Lancet, 2017 - thelancet.com
Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
[HTML][HTML] Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
S De Sanjosé, L Alemany, J Ordi, S Tous… - European journal of …, 2013 - Elsevier
Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN)
and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data …
and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data …
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital …
SK Kjaer, K Sigurdsson, OE Iversen… - Cancer prevention …, 2009 - AACR
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …